· 供应链分析
@Erick_P23 核心逻辑更偏向于共封装光学(CPO)的规模化，预计其复杂性将使MSSCorp成为检测良率方面的垄断型瓶颈（他们声称目标市场份额为90%）。尽管这些技术也可用于其他领域。 $FORM 的产能爬坡早了很多，所以下次财报中营收可能会开始显现？ 无论如何，亚洲概念股因CPO时间表延迟的报道而大幅抛售，但我通过$AMD 大会上的渠道核实发现该报道不实。 我认为我的观点没有改变，更多的是在等待2027年。 像Shunsin这样拥有更多确认的规模化交换机出货量，以及像 $AAOI / $SIVE 这样的激光概念股，其产能爬坡要早得多。在我看来，这只是时间线的问题，以及市场何时愿意对此进行定价。
@Erick_P23 Thesis is more for CPO scale up expecting complexity making make MSSCorp a monopoly-type chokepoint over inspection yields (they were claiming 90% market share target). Although they can be used for other segments. $FORM ramped a lot earlier, so maybe will revenue would start to appear in next earnings? Regardless, Asian names sold off extremely hard on CPO timeline delay report that I found to be incorrect with my channel checks at the $AMD conference. Don't think my views have changed, it's moreso waiting for 2027. Names with more confirmed scale-out switch volumes like Shunsin + laser names like $AAOI / $SIVE ramp a lot earlier. It's just timelines in my view and when markets want to price that in.